[Abatacept in the treatment of rheumatoid arthritis; systematic review and economic evaluation]
Brodszky V, Pentek M, Majer I, Karpati K, Gulacsi L
Record ID 32010001765
Hungarian, English
Authors' recommendations:
Abatacept is an effective treatment for RA compared to placebo in terms of improving symptoms and health related quality of life. The cost utility of the abatacept is between 3.6-8.7 million HUF/QALY compared to methotrexate. Abatacept therapy is dominant strategy compared to cycled TNF-alfa inhibitors.
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://hecon.uni-corvinus.hu/download/english/publ/hecon_research_22_eng.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Hungary
MeSH Terms
- Antirheumatic Agents
- Arthritis, Rheumatoid
- Cost-Benefit Analysis
- Immunoconjugates
Contact
Organisation Name:
Unit of Health Economics and Technology Assessment in Health Care
Contact Address:
Unit of Health Economics and Technology Assessment in Health Care Department of Public Policy and Management Budapest University of Economic Studies 1125 Budapest Fovam ter 8 Budapest HUNGARY Tel: +36 1 218 8197 Fax: +36 1 218 1466
Contact Name:
laszlo.gulacsi@uni-corvinus.hu
Contact Email:
laszlo.gulacsi@uni-corvinus.hu
Copyright:
Unit of Health Economics and Technology Assessment in Health Care (HunHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.